TLP
OCUL icon

Tri Locum Partners’s Ocular Therapeutix OCUL Stock Holding History

Tri Locum Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-514,642
Closed -$3.52M – 24
2024
Q2 		$3.52M Buy
+514,642
New +$3.18M 0.89% 21

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Tri Locum Partners's OCUL Position: Q3 2024 in Review

Tri Locum Partners sold out of Ocular Therapeutix (OCUL) in Q3 2024, closing a stake of 514,642 shares — an estimated $3.52M sold.

Tri Locum Partners first reported a position in OCUL in Q2 2024 and held it in 1 quarter. The position peaked at $3.52M in Q2 2024. 168 funds tracked by Wall St. Rank hold OCUL as of Q3 2024.

  • Tri Locum Partners reported no remaining Ocular Therapeutix position as of Q3 2024 after selling out during the quarter.
  • Tri Locum Partners sold 514,642 Ocular Therapeutix shares in Q3 2024, an estimated $3.52M.
  • Tri Locum Partners first reported a position in Ocular Therapeutix in Q2 2024 and held it in 1 quarter.
  • Tri Locum Partners's Ocular Therapeutix position peaked at $3.52M in Q2 2024.
  • 168 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2024.

Based on Tri Locum Partners's 13F filing for Q3 2024, filed 14 Nov 2024.